No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Disease-modifying effects of finerenone in CKM syndrome
Disease-modifying effects of finerenone in CKM syndrome
ESC Congress 2024
Disease-modifying effects of finerenone in CKM syndrome
- Muthiah Vaduganathan, MD
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
ACC.24
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
- James Januzzi, MD
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC.24
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
- Alexander J. Blood, MD
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
Kidney Disease
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
- Antoni Bayés-Genís, MD, PhD
- Patrick Rossignol, MD, PhD